{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:09:11Z","timestamp":1782234551481,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,3,8]],"date-time":"2015-03-08T00:00:00Z","timestamp":1425772800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12886-015-0001-7","type":"journal-article","created":{"date-parts":[[2015,3,7]],"date-time":"2015-03-07T00:14:12Z","timestamp":1425687252000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease"],"prefix":"10.1186","volume":"15","author":[{"given":"Marcel N","family":"Menke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Framme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Nelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus R","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veit","family":"Sturm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,8]]},"reference":[{"key":"1_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","volume":"84","author":"C Gilbert","year":"2008","unstructured":"Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008;84:77\u201382.","journal-title":"Early Hum Dev"},{"key":"1_CR2","doi-asserted-by":"publisher","first-page":"5177","DOI":"10.1167\/iovs.08-2584","volume":"49","author":"S LEH","year":"2008","unstructured":"LEH S. Through the eyes of a child: understanding retinopathy through ROP: the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2008;49:5177\u201382.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1_CR3","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity randomized trial. Arch Ophthalmol. 2003;121:1684\u201394.","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"1_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603\u201315.","journal-title":"N Engl J Med"},{"issue":"2","key":"1_CR5","doi-asserted-by":"publisher","first-page":"F170","DOI":"10.1136\/archdischild-2011-301148","volume":"98","author":"BA Darlow","year":"2013","unstructured":"Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed. 2013;98(2):F170\u2013174.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"2","key":"1_CR6","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","volume":"153","author":"T Sato","year":"2012","unstructured":"Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153(2):327\u201333. e321.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1_CR7","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1111\/j.1755-3768.2011.02240.x","volume":"90","author":"AM Carneiro","year":"2012","unstructured":"Carneiro AM, Costa R, Falcao MS, Barthelmes D, Mendonca LS, Fonseca SL, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol. 2012;90(1):e25\u201330.","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"1_CR8","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ajo.2012.03.047","volume":"154","author":"TU Krohne","year":"2012","unstructured":"Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012;154(4):682\u20136. e682.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jaapos.2009.10.011","volume":"14","author":"JC Law","year":"2010","unstructured":"Law JC, Recchia FM, Morrison DG, Donahue SP, Estes RL. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS. 2010;14(1):6\u201310.","journal-title":"J AAPOS"},{"issue":"4","key":"1_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4103\/0301-4738.33057","volume":"55","author":"R Azad","year":"2007","unstructured":"Azad R, Chandra P. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol. 2007;55(4):319. author reply 320.","journal-title":"Indian J Ophthalmol"},{"issue":"4","key":"1_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4103\/0301-4738.33053","volume":"55","author":"T Sangtam","year":"2007","unstructured":"Sangtam T, Vinekar A, Maheshwar B, Dogra MR, Eong KG. Intravitreal bevacizumab (Avastin) for post-laser photocoagulation anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol. 2007;55(4):317. author reply 317\u2013318.","journal-title":"Indian J Ophthalmol"},{"issue":"6","key":"1_CR12","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/ICU.0b013e3282f0ca54","volume":"18","author":"CM Andreoli","year":"2007","unstructured":"Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007;18(6):502\u20138.","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"1_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/MOP.0b013e32832925f9","volume":"21","author":"HA Mintz-Hittner","year":"2009","unstructured":"Mintz-Hittner HA, Best LM. Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opin Pediatr. 2009;21(2):182\u20137.","journal-title":"Curr Opin Pediatr"},{"issue":"2","key":"1_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/08820530902800108","volume":"24","author":"KL Lin","year":"2009","unstructured":"Lin KL, Hirose T, Kroll AJ, Lou PL, Ryan EA. Prospects for treatment of pediatric vitreoretinal diseases with vascular endothelial growth factor inhibition. Semin Ophthalmol. 2009;24(2):70\u20136.","journal-title":"Semin Ophthalmol"},{"issue":"1","key":"1_CR15","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1111\/j.1755-3768.2012.02469.x","volume":"91","author":"R Hoerster","year":"2013","unstructured":"Hoerster R, Muether P, Dahlke C, Mehler K, Oberthur A, Kirchhof B, et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol. 2013;91(1):e74\u201375.","journal-title":"Acta Ophthalmol"},{"key":"1_CR16","first-page":"E-abstract 3165","volume":"52","author":"KS Lee SJ","year":"2011","unstructured":"Lee SJ KS, Yoo B, Kim HW, Kim YH. Plasma level of vascular endothelial growth factor in retinopathy of prematurity after intravitreal injection of bevacizumab. Invest Ophthalmol Vis Sci. 2011;52:E-abstract 3165.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"1_CR17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaapos.2009.03.006","volume":"13","author":"H Al-Dhibi","year":"2009","unstructured":"Al-Dhibi H, Khan AO. Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema. J AAPOS. 2009;13(4):400\u20132.","journal-title":"J AAPOS"},{"issue":"8","key":"1_CR18","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1097\/IAE.0b013e3181aade74","volume":"29","author":"PB Knecht","year":"2009","unstructured":"Knecht PB, Michels S, Sturm V, Bosch MM, Menke MN. Tunnelled versus straight intravitreal injection: intraocular pressure changes, vitreous reflux, and patient discomfort. Retina. 2009;29(8):1175\u201381.","journal-title":"Retina"},{"issue":"3","key":"1_CR19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000346397","volume":"229","author":"MN Menke","year":"2013","unstructured":"Menke MN, Salam A, Framme C, Wolf S. Long-term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with ranibizumab. Ophthalmologica. 2013;229(3):168\u201372.","journal-title":"Ophthalmologica"},{"issue":"3","key":"1_CR20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3109\/08820538.2013.771195","volume":"28","author":"G Abedi","year":"2013","unstructured":"Abedi G, Adelman RA, Salim S. Incidence and management of elevated intraocular pressure with antivascular endothelial growth factor agents. Semin Ophthalmol. 2013;28(3):126\u201330.","journal-title":"Semin Ophthalmol"},{"issue":"11","key":"1_CR21","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1136\/bjo.2008.141481","volume":"92","author":"JE Sears","year":"2008","unstructured":"Sears JE. Anti-vascular endothelial growth factor and retinopathy of prematurity. Br J Ophthalmol. 2008;92(11):1437\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"1_CR22","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1089\/jop.2011.0060","volume":"27","author":"BC Harder","year":"2011","unstructured":"Harder BC, von Baltz S, Jonas JB, Schlichtenbrede FC. Intravitreal bevacizumab for retinopathy of prematurity. J Ocul Pharmacol Ther. 2011;27(6):623\u20137.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"3","key":"1_CR23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.4103\/0974-620X.106103","volume":"5","author":"CJ Lin","year":"2012","unstructured":"Lin CJ, Chen SN, Hwang JF. Intravitreal ranibizumab as salvage therapy in an extremely low-birth-weight infant with rush type retinopathy of prematurity. Oman J Ophthalmol. 2012;5(3):184\u20136.","journal-title":"Oman J Ophthalmol"},{"issue":"4","key":"1_CR24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.tjo.2012.10.001","volume":"2","author":"S-NC Chun-Ju Lin","year":"2012","unstructured":"Chun-Ju Lin S-NC, Chien-Chi T, Yao-Chung C, Jiunn-Feng H. Effects of ranibizumab on very low birth weight infants with stage 3 retinopathy of prematurity: a preliminary report. Taiwan J Ophthalmol. 2012;2(4):136\u20139.","journal-title":"Taiwan J Ophthalmol"},{"issue":"7","key":"1_CR25","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1136\/bjophthalmol-2012-302276","volume":"97","author":"MA Castellanos","year":"2013","unstructured":"Castellanos MA, Schwartz S, Garcia-Aguirre G, Quiroz-Mercado H. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol. 2013;97(7):816\u20139.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1_CR26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000338623","volume":"3","author":"A Mota","year":"2012","unstructured":"Mota A, Carneiro A, Breda J, Rosas V, Magalhaes A, Silva R, et al. Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity. Case Rep Ophthalmol. 2012;3(1):136\u201341.","journal-title":"Case Rep Ophthalmol"},{"issue":"3","key":"1_CR27","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/j.1755-3768.2010.02065.x","volume":"89","author":"Y Tano","year":"2011","unstructured":"Tano Y, Ohji M. Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study. Acta Ophthalmol. 2011;89(3):208\u201317.","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"1_CR28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ophtha.2012.07.026","volume":"120","author":"R Silva","year":"2013","unstructured":"Silva R, Axer-Siegel R, Eldem B, Guymer R, Kirchhof B, Papp A, et al. The SECURE study: long-term safety of ranibizumab 0.5\u00a0mg in neovascular age-related macular degeneration. Ophthalmology. 2013;120(1):130\u20139.","journal-title":"Ophthalmology"},{"issue":"10","key":"1_CR29","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.ophtha.2013.02.019","volume":"120","author":"GE Lang","year":"2013","unstructured":"Lang GE, Berta A, Eldem BM, Simader C, Sharp D, Holz FG, et al. Two-year safety and efficacy of Ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology. 2013;120(10):2004\u201312.","journal-title":"Ophthalmology"},{"issue":"11","key":"1_CR30","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014;132(11):1327\u201333.","journal-title":"JAMA Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-015-0001-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-015-0001-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-015-0001-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-015-0001-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T12:37:54Z","timestamp":1551184674000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-015-0001-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,8]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1"],"URL":"https:\/\/doi.org\/10.1186\/s12886-015-0001-7","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,8]]},"assertion":[{"value":"6 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"20"}}